SG Americas Securities LLC Buys Shares of 15,800 Pyxis Oncology, Inc. (NASDAQ:PYXS)

SG Americas Securities LLC purchased a new position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) during the third quarter, Holdings Channel.com reports. The fund purchased 15,800 shares of the company’s stock, valued at approximately $58,000.

Several other hedge funds have also made changes to their positions in PYXS. StemPoint Capital LP bought a new position in Pyxis Oncology during the 1st quarter worth $7,643,000. Ikarian Capital LLC acquired a new position in shares of Pyxis Oncology during the first quarter valued at $7,082,000. Vanguard Group Inc. grew its position in shares of Pyxis Oncology by 7.3% during the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock worth $5,970,000 after acquiring an additional 94,740 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Pyxis Oncology by 125.3% in the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after acquiring an additional 743,499 shares during the period. Finally, Blue Owl Capital Holdings LP bought a new stake in Pyxis Oncology in the 2nd quarter valued at about $3,462,000. Institutional investors own 39.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They issued a “buy” rating and a $10.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research report on Friday, August 16th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday, September 19th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $9.00.

Pyxis Oncology Price Performance

NASDAQ PYXS opened at $3.79 on Tuesday. The company’s 50 day simple moving average is $3.57 and its 200 day simple moving average is $3.69. The firm has a market capitalization of $225.20 million, a PE ratio of -3.06 and a beta of 1.27. Pyxis Oncology, Inc. has a 12 month low of $1.35 and a 12 month high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. Sell-side analysts anticipate that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current fiscal year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.